Understand this story
On November 8, 2026, MegaStream TechBio, jointly founded by Harbour BioMed and BioMap, held a strategic cooperation agreement signing ceremony. On the same day, Shangguan News reported that the company proposed the "AIDD 3.0: AI×Bio dual-native" concept, placing model R&D, dry and wet experiments, and drug development within the same system for iteration; it has advanced the first batch of 5 innovative pipelines, with some AI-designed molecules achieving preliminary experimental validation progress, and the first project aims to submit an IND in the first half of 2027. MegaStream OS builds its core platform around target discovery, molecule generation and optimization, and immunogenicity engineering. There are currently no reports of further progress following the signing.
AI-generated from public reports
Latest development · Report
MegaStream proposes AIDD 3.0 dual-native model, with the first 5 pipelines advancing to IND filingDevelopments
1 confirmed developments
MegaStream and two co-founders hold a strategic cooperation agreement signing
Source:Shangguan News
Reports and discussion timeline
Browse reports and discussion by time. Their evidence levels remain distinct.
Nov 8
Shanghai Observer
MegaStream proposes AIDD 3.0 dual-native model, with the first 5 pipelines advancing to IND filing
MegaStream TechBio, jointly founded by Harbour BioMed and BioMap, has proposed the concept of "AIDD 3.0: AI×Bio dual-native," integrating model R&D, dry and wet experiments, and drug development into a single system for iteration. The company has advanced its first batch of 5 innovative pipelines, with some AI-designed molecules achieving preliminary experimental validation progress, and the first project is targeted for IND filing in the first half of 2027. MegaStream OS builds its core platform around target discovery, molecule generation and optimization, and immunogenicity engineering.
Yicai
AI drug discovery moves beyond outsourced collaboration: pharma companies such as MegaStream are embedding AI into the R&D backbone
AI drug discovery is shifting from undertaking outsourced R&D to building its own AI drug R&D infrastructure, consolidating models, data and experimental capabilities into a single entity. Lei Ming, CEO of MegaStream, jointly founded by Harbour BioMed and BioMap, said that the value of AI must be reflected in differentiated drugs, R&D success rates or efficiency, rather than in model parameters and algorithm metrics. A neuroscience target discovered by Recursion and Genentech using 30 million neural cell images entered the early development stage of small-molecule drugs in August 2026.